➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Merck
Dow
McKesson
Moodys

Last Updated: June 22, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019813


Email this page to a colleague

« Back to Dashboard

NDA 019813 describes DURAGESIC-75, which is a drug marketed by Janssen Pharms and is included in one NDA. It is available from one supplier. Additional details are available on the DURAGESIC-75 profile page.

The generic ingredient in DURAGESIC-75 is fentanyl. There are thirty-one drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the fentanyl profile page.
Summary for 019813
Tradename:DURAGESIC-75
Applicant:Janssen Pharms
Ingredient:fentanyl
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 019813
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 019813
Suppliers and Packaging for NDA: 019813
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DURAGESIC-100 fentanyl FILM, EXTENDED RELEASE;TRANSDERMAL 019813 NDA Janssen Pharmaceuticals, Inc. 50458-101 50458-101-05 5 POUCH in 1 BOX (50458-101-05) > 1 PATCH in 1 POUCH
DURAGESIC-12 fentanyl FILM, EXTENDED RELEASE;TRANSDERMAL 019813 NDA Janssen Pharmaceuticals, Inc. 50458-101 50458-101-05 5 POUCH in 1 BOX (50458-101-05) > 1 PATCH in 1 POUCH
Paragraph IV (Patent) Challenges for 019813
Tradename Dosage Ingredient NDA Submissiondate
DURAGESIC-37 FILM, EXTENDED RELEASE;TRANSDERMAL fentanyl 019813
DURAGESIC-100 FILM, EXTENDED RELEASE;TRANSDERMAL fentanyl 019813
DURAGESIC-50 FILM, EXTENDED RELEASE;TRANSDERMAL fentanyl 019813
DURAGESIC-12 FILM, EXTENDED RELEASE;TRANSDERMAL fentanyl 019813
DURAGESIC-75 FILM, EXTENDED RELEASE;TRANSDERMAL fentanyl 019813
DURAGESIC-25 FILM, EXTENDED RELEASE;TRANSDERMAL fentanyl 019813

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength100MCG/HR
Approval Date:Aug 7, 1990TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength75MCG/HR
Approval Date:Aug 7, 1990TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength50MCG/HR
Approval Date:Aug 7, 1990TE:ABRLD:Yes

Expired US Patents for NDA 019813

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Janssen Pharms DURAGESIC-25 fentanyl FILM, EXTENDED RELEASE;TRANSDERMAL 019813-004 Aug 7, 1990   Try Before You Buy   Try Before You Buy
Janssen Pharms DURAGESIC-25 fentanyl FILM, EXTENDED RELEASE;TRANSDERMAL 019813-004 Aug 7, 1990   Try Before You Buy   Try Before You Buy
Janssen Pharms DURAGESIC-50 fentanyl FILM, EXTENDED RELEASE;TRANSDERMAL 019813-003 Aug 7, 1990   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Medtronic
AstraZeneca
Moodys
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.